Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
J Med Chem
; 46(3): 349-52, 2003 Jan 30.
Article
in En
| MEDLINE
| ID: mdl-12540232
ABSTRACT
Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyridazines
/
Mitogen-Activated Protein Kinases
/
Enzyme Inhibitors
Limits:
Animals
Language:
En
Journal:
J Med Chem
Journal subject:
QUIMICA
Year:
2003
Document type:
Article
Affiliation country:
United States